PRM-151

BIOLOGICAL3 trials

Sponsors

Hoffmann-La Roche

Conditions

GlaucomaIdiopathic Pulmonary Fibrosis

Phase 1

A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

CompletedNCT01254409

Hoffmann-La RocheIdiopathic Pulmonary Fibrosis

Start: 2011-03-29End: 2012-07-02Updated: 2022-04-20

Phase 2

PRM-151 in the Prevention of Scarring Following Trabeculectomy

CompletedNCT01064817

Hoffmann-La RocheGlaucoma

Start: 2010-06-14End: 2012-11-14Updated: 2022-04-28

A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

CompletedNCT02550873

Hoffmann-La RocheIdiopathic Pulmonary Fibrosis

Start: 2015-09-01End: 2017-05-02Updated: 2022-05-02

Related Papers

Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial

American Journal of Respiratory and Critical Care Medicine2024-02-1437 citations

An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis

ERJ Open Research2024-01-013 citations

Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study

Respiratory Research2022-05-2128 citations

Recombinant human pentraxin-2 for idiopathic pulmonary fibrosis: Design of STARSCAPE-OLE, a Phase III open label extension study

2021-09-051 citations

Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) for Idiopathic Pulmonary Fibrosis: Study Design of STARSCAPE, A Phase III Randomized Double Blind Placebo Controlled Trial

2021-05-011 citations

Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.

2019-05-2069 citations

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis

JAMA2018-05-20220 citations